Evidence map›Paper›PMID 42724552›Full record

ArticleAmerican journal of cancer research2026

IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway.

Xueshan Pan, Yue Wang, Jingjing Luo, Xingna Dai, Jialin Zhang, Rui Zheng, Hui Xu, Yingjie Zhang, Jifeng Zhang, Zhiwei Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xueshan PanBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.
Yue WangBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.
Jingjing LuoBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.
Xingna DaiBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.
Jialin ZhangBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.
Rui ZhengBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.
Hui XuDepartment of Laboratory Medicine, School of Laboratory Medicine, Bengbu Medical University Bengbu 233030, Anhui, China.
Yingjie ZhangDepartment of Laboratory Medicine, School of Laboratory Medicine, Bengbu Medical University Bengbu 233030, Anhui, China.
Jifeng ZhangSchool of Biological Engineering and Institute of Digital Ecology and Health, Huainan Normal University Huainan 232038, Anhui, China.
Zhiwei WangDepartment of Biochemistry and Molecular Biology, School of Laboratory Medicine, Bengbu Medical University Bengbu 233030, Anhui, China.
Tong CaoDepartment of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University Bengbu 233004, Anhui, China.
Jia MaBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-23 (IL-23) is a pivotal cytokine implicated in tumor progression and immune evasion, yet its precise molecular mechanisms remain incompletely characterized. In this study, we elucidate that IL-23 upregulates METTL16, which in turn enhances PD-L1 expression and facilitates tumor immune escape. Integrated analysis of TCGA and GEO datasets revealed the co-upregulation of IL-23 and METTL16 in lung and colon carcinomas, both of which are correlated with poor clinical outcomes. Mechanistically, IL-23 induces METTL16 expression in cancer cells via JAK-STAT3 pathway-mediated transcriptional activation. Notably, METTL16 augments PD-L1 levels via an m6A-independent mechanism by directly binding to PD-L1 and impeding its SPOP-mediated ubiquitination and proteasomal degradation. In vivo, METTL16 promotes colon cancer xenograft growth while concurrently suppressing CD8

Indexed as

colon cancerIL-23immune evasionMETTL16PD-L1

Identifiers

PMID42724552
PMCPMC13559380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.